Shares of Unicycive Therapeutics, Inc. (UNCY) are falling about 46 percent in Tuesday morning trading after the company announced that it has received a Complete Response Letter or CRL from the U.S. Food and Drug Administration regarding the resubmitted New Drug Application for oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis.
The company's stock is currently trading at $4.1050, down 46.69 percent or $3.5950, from the previous close of $7.70 on the Nasdaq. It has traded between $3.71 and $8.74 in the past one year.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.